Literature DB >> 11301351

H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis.

A Sakamoto1, Y Oda, T Adachi, Y Oshiro, S Tamiya, K Tanaka, S Matsuda, Y Iwamoto, M Tsuneyoshi.   

Abstract

Dedifferentiated chondrosarcomas, which are known for their poor prognosis, are characterized by conventional chondrosarcoma with high-grade anaplastic components. Activating mutations in ras genes are a common genetic abnormality in human malignancies. The presence of point mutations at codons 12 and 13 of the H-ras gene was studied in 20 formalin-fixed paraffin-embedded chondrosarcomas, comprising 11 cases of conventional chondrosarcoma (six Grade 1 cases and five Grade 2 cases) and nine cases of dedifferentiated chondrosarcoma, using polymerase chain reaction-restriction fragment length polymorphism and direct sequencing analysis. H-ras mutations were only seen in two out of the nine cases of dedifferentiated chondrosarcoma (2/9, 22%) and they were not seen in any of the cases of conventional chondrosarcoma (0/11, 0%). Dedifferentiated chondrosarcomas had a worse prognosis than conventional chondrosarcomas (P < .01); among the patients with dedifferentiated chondrosarcomas, those with H-ras mutation (n = 2) tended to have a worse prognosis than those without (n = 7), although the difference was not statistically significant (P = 0.068). Our results would seem to suggest that H-ras mutation may occur during the course of dedifferentiation and may also have some effect on malignant potential.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11301351     DOI: 10.1038/modpathol.3880313

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

Review 1.  GISTogram: a graphic presentation of the growing GIST complexity.

Authors:  Riccardo Ricci; Angelo Paolo Dei Tos; Guido Rindi
Journal:  Virchows Arch       Date:  2013-08-23       Impact factor: 4.064

2.  Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.

Authors:  Karina A Galoian; Toumy Guettouche; Biju Issac; Amir Qureshi; H T Temple
Journal:  Tumour Biol       Date:  2013-11-01

3.  Dedifferentiated chondrosarcoma with leukocytosis and elevation of serum G-CSF. A case report.

Authors:  Akio Sakamoto; Hidetaka Yamamoto; Kazuhiro Tanaka; Shuichi Matsuda; Katsumi Harimaya; Yoshinao Oda; Masazumi Tsuneyoshi; Yukihide Iwamoto
Journal:  World J Surg Oncol       Date:  2006-07-04       Impact factor: 2.754

4.  Dedifferentiated chondrosarcoma: our clinico-pathological experience and dilemmas in 25 cases.

Authors:  Jelena Sopta; Aleksandar Dordević; Goran Tulić; Vesna Mijucić
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

5.  De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features.

Authors:  Oddmund Søvik; Suzanne Schubbert; Gunnar Houge; Solrun J Steine; Gunnar Norgård; Bernt Engelsen; Pål R Njølstad; Kevin Shannon; Anders Molven
Journal:  J Med Genet       Date:  2007-07       Impact factor: 6.318

6.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.